Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Sirnagen Therapeutics Corporation currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution focus. The alignment of the action with the assigned unit suggests a specific technical niche for the current intellectual property efforts.
The busiest examiner for this portfolio is GIBBS, TERRA C, who is responsible for 1 busiest_examiner_pending. This individual workload matches the total volume of 1 pending office action for the entire portfolio, reflecting a direct relationship between the examiner and the pending matters. Practitioners should note that with only 1 distinct examiner involved, the progress of the matters depends on the specific review pace of this individual.
Because there is only 1 distinct art unit involved, the prosecution strategy does not currently require navigating different procedural norms across multiple units. The presence of the action under GIBBS, TERRA C means that upcoming responses will be directed to this specific individual. This concentration simplifies the communication channel for the current workload in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261882 | COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT | YU, DAVID TUYANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281251 | Composition for Administration of Double-Stranded Oligonucleotide Structures Using Ultrasonic Nebulizer for Prevention or Treatment of Respiratory Viral Infection Including COVID-19, Pulmonary Fibrosis Caused by Viral Infection, or Respiratory Diseases | GIBBS, TERRA C | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281251 | Composition for Administration of Double-Stranded Oligonucleotide Structures Using Ultrasonic Nebulizer for Prevention or Treatment of Respiratory Viral Infection Including COVID-19, Pulmonary Fibrosis Caused by Viral Infection, or Respiratory Diseases | GIBBS, TERRA C | 1635 | §103§112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18261882 | COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT | YU, DAVID TUYANG | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Jul 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial